2,3-butanedione-2-monoxime | 110828-81-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,3-butanedione-2-monoxime
• 英文别名: butane-2,3-dione monoxime；butanedione monooxime；Diacetyl monooxime；biacetyl monoxime；diacetyl monoxime；biacetylmonoxime；(3Z)-3-hydroxyimino-butan-2-one；(3Z)-3-hydroxyiminobutan-2-one
• CAS: 110828-81-4
• 化学式: C₄H₇NO₂
• 分子量: 101.105
• InChiKey: FSEUPUDHEBLWJY-HYXAFXHYSA-N

物化性质

• 沸点：
  185.5±9.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)
• 物理描述：
  2-oxime 2,3-butanedione is a cream-colored powder. (NTP, 1992)
• 熔点：
  76.8 °C
• 溶解度：
  10 to 50 mg/mL at 64° F (NTP, 1992)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Lactose 、 2,3-butanedione-2-monoxime 在 NaOH buffer 、 2-羟基丙烷-1,2,3-三羧酸根 作用下， 以 水 为溶剂， 反应 0.67h， 以22%的产率得到
  参考文献：
  名称：

  Pozo, Marcos; Gotor, Vicente, Journal of the Chemical Society. Perkin transactions I, 1993, # 9, p. 1001 - 1002

  摘要：

  DOI：

文献信息

• Certain antihypertensive 1-[2-[3-carbamoyl-4-hydroxy phenoxy]alkylene
  申请人：Ciba-Geigy Corporation

  公开号：US04559354A1

  公开（公告）日：1985-12-17

  The invention relates to novel substituted phenyl ethers of the formula ##STR1## in which Ar represents a mono- or bi-cyclic carbocyclic aryl radical, or a mono- or bi-cyclic heterocyclic aryl radical bonded to a phenylene radical by way of a ring carbon atom, Ph represents a phenylene radical, n has the value 0 to 1 and alk represents alkylene having from 2 to 5 carbon atoms, the nitrogen atom and the oxygen atom or, if n is 0, the aromatic radical being separated from each other by at least two carbon atoms in the unbranched chain, and R.sub.1 and R.sub.2 each represents, independently of the other, hydrogen or lower alkyl, or together represent lower alkylene, oxa-lower alkylene, thia-lower alkylene, aza-lower alkylene or N-lower alkyl-aza-lower alkylene, and salts thereof, especially pharmaceutically acceptable non-toxic acid addition salts. Such compounds possess, on the one hand, blocking properties towards .beta.-adrenergic receptors and can therefore be used as .beta.-receptor-blockers with or without cardioselectivity for the treatment of Angina pectoris, hypertrophic cardiomyopathy and heart rhythm disorders and also as blood-pressure-reducing agents. On the other hand, such compounds possess .beta.-receptor-stimulating properties and can therefore be used as positively inotropically active agents, especially as cardiotonics, for the treatment of heart muscle insufficiency.

  该发明涉及新型取代苯醚化合物，其化学式为##STR1##其中Ar代表单环或双环碳环芳基，或通过环碳原子与苯基相连的单环或双环杂环芳基，Ph代表苯基，n取值为0至1，alk代表具有2至5个碳原子的烷基，氮原子和氧原子或者如果n为0，则芳基在直链中至少被至少两个碳原子分隔，R.sub.1和R.sub.2分别独立地代表氢或低烷基，或者一起代表低烷基，氧杂低烷基，硫杂低烷基，氮杂低烷基或N-低烷基-氮杂低烷基，以及其盐，特别是药学上可接受的无毒酸盐。这类化合物一方面具有对β-肾上腺素受体的阻滞作用，因此可用作具有或不具有心脏选择性的β-受体阻滞剂，用于治疗心绞痛、肥厚型心肌病和心律失常，也可用作降压药。另一方面，这类化合物具有β-受体激动作用，因此可用作具有正肌力作用的药剂，特别是作为心力衰竭的治疗药物。
• Synthesis, structure and reactivity of cobalt(III) complexes with tridentate imino- and amino-oxime ligands
  作者：Laura Catalano、Renata Dreos、Giorgio Nardin、Lucio Randaccio、Giovanni Tauzher、Sara Vuano

  DOI：10.1039/dt9960004269

  日期：——

  produces a nucleophilic cobalt(I) species which, on reaction with MeI, gives a stable organocobalt dinuclear complex, previously reported. On the contrary, the reduction of [CoIIIL12]ClO4 involves hydrogenation of the ligand from imino- to amino-oxime, with the formation of a stable cobalt(II) species. Under these conditions, no reduction to CoI was observed. The different reactivity is attributed to the

  三齿亚氨基肟HL 2和HL 1是通过联乙酰一肟与2-（2-氨基乙基）吡啶和2-（氨基甲基）吡啶缩合制备的。它们在氧气存在下与钴（II）离子反应，生成配合物[Co III L 2 ] ClO 4（L = L 1或L 2）。亚氨基肟可在NaBH 4存在下氢化，得到相应的氨基肟HL 3和HL 4，它们在与Co II反应后形成配合物[Co III L（HL）] [ClO 4 ] 2。（L = L 3或L 4）。所有这些配合物都已通过单晶X射线衍射进行了结构表征。钴具有八面体环境，其中亚氨基肟配体为mer构型，而氨基肟配体为fac构型。用NaBH 4还原[Co III L 2 2 ] ClO 4产生亲核钴（I）物种，该物种在与MeI反应后可得到稳定的有机钴双核络合物，先前已有报道。相反，[Co III L 1 2 ] ClO 4的还原涉及将配体从亚氨基肟氢化为氨基肟，并形成稳定的钴（II）物种。在这些条件下，未观察到Co
• General Route to Racemic and Enantiomeric Carbo- and Heterocyclic Vinyl Sulfoxides via Tandem Michael Addition/Horner Olefination of α-Phosphorylvinyl Sulfoxides
  作者：Marian Mikołajczyk、Jerzy A. Krysiak、Wanda H. Midura、Michał W. Wieczorek、Ewa Różycka-Sokołowska

  DOI：10.1021/jo061463b

  日期：2006.11.1

  heterocyclic and carbocyclic vinyl sulfoxides has been developed which involves reaction of α-phosphorylvinyl sulfoxides with carbonyl compounds bearing oxygen, nitrogen, and carbon nucleophilic centers. Use of optically active α-phosphorylvinyl p-tolyl sulfoxides in this tandem Michael addition/Horner olefination reaction leads to the corresponding optically active cyclic sulfoxides. In this way, a variety of

  已经开发了杂环和碳环乙烯基亚砜的新的一锅法合成，其涉及α-磷酰基乙烯基亚砜与带有氧，氮和碳亲核中心的羰基化合物的反应。在该串联的迈克尔加成/霍纳烯化反应中使用光学活性的α-磷酰基乙烯基对甲苯基亚砜会产生相应的光学活性的环亚砜。以这种方式，已经有效地制备了各种旋光的苯甲基，吡咯嗪，喹诺啉和环戊烯亚砜。
• SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTI-ATHEROSCLEROTIC, ANTI-DYSLIPIDEMIC, ANTI-DIABETIC AND ANTI-OBESITY AGENTS AND METHOD
  申请人：Tino A. Joseph

  公开号：US20080009533A1

  公开（公告）日：2008-01-10

  Compounds are provided which have the structure of Formula (I): wherein R 1 is halogen; and X is hydrogen or halogen, and salts thereof, which compounds are useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic, and anti-obesity agents.

  提供了具有以下结构式（I）的化合物： 其中R1是卤素; X是氢或卤素，并且它们的盐，这些化合物可用作抗动脉粥样硬化、抗血脂异常、抗糖尿病和抗肥胖剂。
• Novel and Efficient Synthesis of N,N-dialkylamino-O-alkyl-2-(1-methyl-2-oxopropylidene)phosphorohydrazido Oximes. Part 3.
  作者：Rajesh Kumar、Arvind Gupta、Mahabir Kaushik

  DOI：10.3390/12092193

  日期：——

  A novel and efficient method has been developed for the synthesis of N,N-dialkylamino-O-alkyl-2-(1-methyl-2-oxopropylidene)phosphorohydrazido oximes 5. The reactions involve the condensation of diacetylmonoxime and N,N-dialkylamino-O- alkylphosphorohydrazides in the presence of activated silica and give the corresponding target oximes in excellent yields under mild conditions.

  开发了一种新颖有效的合成N,N-二烷基氨基-O-烷基-2-(1-甲基-2-氧亚丙基)磷酰肼肟5的方法。该反应涉及二乙酰单肟和N,N-二烷基氨基的缩合-O-烷基磷酰肼在活性二氧化硅存在下发生反应，并在温和条件下以优异的收率得到相应的目标肟。